JianguoTaoMD
Pathology • Charlottesville, VAHematopathology, Anatomic Pathology, Clinical Pathology
Assistant Professor, Oncologic Sciences, USF-Morsani
Dr. Tao is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1215 Lee St
Charlottesville, VA 22908Phone+1 888-882-3990Fax+1 434-243-6499
Education & Training
Zucker School of Medicine at Hofstra/NorthwellResidency, Pathology-Anatomic and Clinical, 1996 - 2000
Henan Medicine UniversityClass of 1985
Certifications & Licensure
VA State Medical License 2021 - 2026
FL State Medical License 2002 - 2024
GA State Medical License 2021 - 2023
NY State Medical License 2021 - 2023
PA State Medical License 2000 - 2001- American Board of Pathology Anatomic Pathology & Clinical Pathology
- American Board of Pathology Hematology
Publications & Presentations
PubMed
- 238 citationsCoordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell LymphomasXinwei Zhang, Xiaohong Zhao, Warren Fiskus, Jianhong Lin, Tint Lwin
Cancer Cell. 2012-10-16 - 149 citationsmiR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathwayJianjun Zhao, Jianhong Lin, Di Zhu, Xujun Wang, Daniel J. Brooks
Cancer Research. 2014-03-15 - 274 citationsmicroRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphomaJian-jun Zhao, Jianhong Lin, Tint Lwin, Hua Yang, Jianping Guo
Blood. 2010-04-01
Press Mentions
Iron Chelation and 2‐Oxoglutarate‐Dependent Dioxygenase Inhibition Suppress Mantle Cell Lymphoma's Cyclin D1September 13th, 2019
Uncovering, Reversing Venetoclax Resistance in LymphomaJuly 17th, 2019
Why Lymphoma Patients May Become Resistant to Specific TherapyMay 16th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
